Perfusion Abnormalities in Hypertrophic Cardiomyopathy

April 13, 2026 updated by: Jonathan Lindner, MD, University of Virginia

Myocardial Perfusion Abnormalities in Hypertrophic Cardiomyopathy

The purpose of this study is to investigate whether myocardial microvascular perfusion in patients with hypertrophic cardiomyopathy improved after initiation of cardiac myosin inhibitor therapy.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Virginia
      • Charlottesville, Virginia, United States, 22903
        • University of Virginia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with HCM who are being started on cardiac myosin inhibitor therapy.

Description

Inclusion Criteria:

  • Diagnosis of hypertrophic cardiomyopathy
  • Subject being initiated on clinically-indicated cardiac myosin inhibitor therapy

Exclusion Criteria:

  • Pregnancy
  • Lactation
  • Allergy to ultrasound enhancing agent (lipid-stabilized) or regadenoson
  • Serious AE to regadenoson
  • Hypotension
  • Serious bradycardia not addressed by pacemaker
  • Moderate or greater reactive airways disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with HCM initiated on cardiac myosin inhibitor therapy
Patients with HCM who are being initiated on cardiac myosin inhibitor therapy for clinically indicated reasons.
Diagnostic test: myocardial contrast echo
Vasodilator stress myocardial contrast echocardiography will be performed at baseline and within 4 months of reaching target dose of a cardiac myosin inhibitor.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Peak hyperemic perfusion
Time Frame: 3 months
Myocardial contrast echo-derived myocardial blood flow at peak hyperemia (produced by regadenoson)
3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Resting myocardial perfusion
Time Frame: 3 months
Resting myocardial perfusion by MCE
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Virginia

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 2, 2025

Primary Completion (Estimated)

May 30, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

September 13, 2024

First Submitted That Met QC Criteria

September 13, 2024

First Posted (Actual)

September 19, 2024

Study Record Updates

Last Update Posted (Actual)

April 16, 2026

Last Update Submitted That Met QC Criteria

April 13, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 301910

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified data on patient demographics, HCM type, medication dose, transthoracic echo data, MCE perfusion imaging data at rest and during regadenoson

IPD Sharing Time Frame

December 2024; End-date not determined but no sooner than December 2028

IPD Sharing Access Criteria

Any investigators requesting access to data after publication of results.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertrophic Cardiomyopathy (HCM)

Clinical Trials on myocardial contrast echo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe